Canada-wide Implementation of a Virtual Sexual Health and Rehabilitation eClinic (SHAReClinic) for Prostate Cancer Patients and Their Partners
Recruiting
The goal of this observational study is to evaluate the effectiveness of SHAReClinic, a national, virtual Sexual Health and Rehabilitation eClinic designed to support prostate cancer patients and their partners. Specifically, this study aims to assess SHAReClinic's impact on improving sexual function, satisfaction, and relational intimacy after treatment. The primary objective is to evaluate SHAReClinic's effectiveness across participating sites and determine its role in supporting long-term se... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Vancouver Coastal Health Authority, Vancouver, British Columbia +9 locations
Conditions: Prostate Cancer, Sexual Dysfunction, Physiological, Sexual Dysfunction, Psychological, Sexual Dysfunction, Virtual Care, Virtual Clinic, Survivorship, Implementation of Evidence Based Programs, Implementation
Bariatric Surgery for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium
Recruiting
A growing population of young women with obesity are developing atypical hyperplasia (pre-cancer) and endometrial cancer. Progestin is the standard treatment for women who wish to preserve fertility, but this approach does not address the underlying cause of endometrial cancer/atypical hyperplasia (obesity); thus response rates are low and recurrence rates are high. Significant weight loss by bariatric surgery, in combination with progestin therapy may result in greater and more durable response... Read More
Gender:
FEMALE
Ages:
Between 18 years and 41 years
Trial Updated:
03/11/2025
Locations: Princess Margaret Hospital, Toronto, Ontario
Conditions: Endometrial Cancer, Atypical Hyperplasia, Bariatric Surgery Candidate
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Recruiting
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Gender:
ALL
Ages:
Between 0 years and 20 years
Trial Updated:
03/11/2025
Locations: Phoenix Children's Hospital, Phoenix, Arizona +50 locations
Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Hemophilia, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
ED to EPI: Using SMS to Improve the Transition from the Emergency Department to Early Psychosis Intervention
Recruiting
Psychosis is a disabling condition that typically has its onset in adolescence and early adulthood. Many young people with psychosis have difficulty navigating services or are reluctant to engage in treatment until their illness becomes an emergency. Consequently, nearly half of all new psychotic disorders are diagnosed in the emergency department (ED). Despite the rationale and evidence for early psychosis intervention (EPI), around half of youth do not access these services. The investigators... Read More
Gender:
ALL
Ages:
Between 16 years and 29 years
Trial Updated:
03/11/2025
Locations: Centre for Addiction and Mental Health, Toronto, Ontario
Conditions: First Episode Psychosis, Psychosis, Psychotic Episode, Psychoses, Affective, Bipolar Disorder, Depressive Psychosis, Schizoaffective Disorder, Schizophreniform Disorders, Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Substance Induced Psychoses
5500/20 Vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)
Recruiting
We will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam radiotherapy (EBRT) for treating the prostate in patients with oligometastatic prostate cancer. Secondary aims include assessment of progression-free survival (PFS) and overall survival (OS) as well as cost-effectiveness. We hypothesize that ultrahypofractionation will maintain favorable toxicity profiles and quality... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: British Columbia Cancer Agency Center for the Southern Interior, Kelowna, British Columbia +3 locations
Conditions: Oligometastatic Prostate Cancer
Feasibility of Early Swallowing and Speech Intervention for Head and Neck Cancer Patients Treated SURGically
Recruiting
Oral cavity cancer (OCC) is one of the most common cancers worldwide, with tongue cancer being one of the most common subtypes. Patients with oral cancers can experience painful swallowing, swallowing difficulty (dysphagia), and associated weight loss long after surgery. Not only is dysphagia an independent predictor of quality of life (QoL) in cancer survivorship, it can also have a devastating impact on the health of patients resulting from complications such as pneumonia, malnutrition and fee... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: University Health Network, Toronto, Ontario
Conditions: Dysphagia, Head and Neck Cancer
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients with Advanced Solid Tumors
Recruiting
This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of three parts. Part 1 is dose-escalation part. In part 1, the safety and tolerability of YL211 in patients with selected advanced solid tumors will be evaluated and the MTD and RED will be determined. Part 2 is backfill enrollment part. We will further estimate the safety and efficacy of YL211 in patients with selected adcance tumor to select the RED(s) of YL211. Part 3 is... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado +12 locations
Conditions: Advanced Solid Tumors
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Recruiting
Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Cross Cancer Institute, Edmonton, Alberta +9 locations
Conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
Recruiting
This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta +1 locations
Conditions: Myeloma, Myeloma Multiple
Inflammation REduction to Prevent CArdiovascular Injury in Renal Disease (REPAIR)
Recruiting
Phase 1 basket trial including 2 open-label single-arm cohorts: REPAIR CKD cohort and REPAIR Dialysis cohort. Open label colchicine 0.3 mg daily for 8 weeks followed, in patients who tolerated the 0.3 mg dose, by forced titration to 0.6 mg daily for 8 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: University of Alberta Hospital, Edmonton, Alberta +2 locations
Conditions: Chronic Kidney Diseases, Renal Failure
The IMPACT Implementation-Effectiveness Trial
Recruiting
More Canadians are surviving cancer, however, individuals with cancer live with side effects for years after treatments have ended. The physical and psychosocial benefits of regular physical activity (PA) during and after cancer treatment are well established. However, less than 30% of individuals with cancer meet current PA recommendations and PA levels decline significantly during treatment. PA services within the cancer institution to support well-being during treatment are not available for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Joseph Brant Hospital, Burlington, Ontario +2 locations
Conditions: Cancer
Personalized Pharmacotherapy Using Pharmacogenetics in Veterans
Recruiting
This study is an observational clinical trial aimed at to evaluate the use of pharmacogenetic testing (PGx) for mental health treatment in members and Veterans of the CAF and RCMP patient population as well as the attitudes of both St. Joseph's OSI Clinic Psychiatrists and patients towards PGx. Both OSI Clinic Psychiatrists participants and patient participants will be administered a brief demographic survey in addition to a survey examining their views on, and current knowledge of PGx. Patient... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: MacDonald Franklin OSI Research and Innovation Centre, London, Ontario
Conditions: Pharmacogenetic Testing to Determine Pharmacological Treatment in PTSD